LIGAND PHARMACEUTICALS INCORPORATED Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $84.48 per share as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2026-02-27
- 2025-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $84.48.
- 2024-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $75.14.
- 2023-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $65.70.
- 2022-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $61.31.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2025-12-31 | $84.48 10-K · filed 2026-02-27 | |
| 2024-12-31 | $75.14 10-K · filed 2025-02-28 | |
| 2023-12-31 | $65.70 10-K · filed 2024-02-29 | |
| 2022-12-31 | $61.31 10-K · filed 2023-02-28 | |
| 2014-12-31 | $28.78 10-K · filed 2015-02-23 | $16.79 10-K · filed 2014-12-01 |
| 2013-12-31 | $16.79 10-K/A · filed 2014-12-12 | |
| 2012-12-31 | $14.90 10-K · filed 2013-03-14 |